Smsbiotech Inc. has gained clearance in Australia to begin a phase I trial of its small mobile stem (SMS) cell therapy for chronic obstructive pulmonary disease (COPD).
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
A new in vivo approach to chimeric antigen receptor T-cell (CAR-T) therapy could extend the technology’s use beyond cancer, as a treatment for autoimmune disease (Science 2025, DOI: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback